Announcements Trials

Browse Landscape

Phase

Phase NA 1 Phase 3 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Small Cell Lung Carcinoma 1 Recurrence 1 Ovarian Neoplasms 1 Lymphoma, Non-Hodgkin 1 Carcinoma, Hepatocellular 1

Interventions

Etoposide 18 Carboplatin 18 pembrolizumab 15 Nivolumab 11 Cisplatin 11 atezolizumab 8 Topotecan 8 Irinotecan 7 Temozolomide 6 Paclitaxel 5 PM 01183 5 Ipilimumab 5 Gemcitabine 5 olaparib 4 Radiotherapy 4 Docetaxel 4 surufatinib 3 durvalumab 3 carfilzomib 3 Bevacizumab 3 veliparib 2 trilaciclib 2 sacituzumab govitecan 2 rovalpituzumab tesirine 2 obatoclax 2 niraparib 2 navitoclax 2 lorvotuzumab mertansine 2 lenvatinib 2 fluzoparib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Small Cell Lung Carcinoma × chiauranib × Clear all

NCT05271292 2024-07-16

SCLC

Chipscreen Biosciences, Ltd.

Phase 1/2 Recruiting

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡